Phase II evaluation of dalantercept, a soluble recombinant activin receptor-like kinase 1 (ALK1) receptor fusion protein, for the treatment of recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group Study 0229N
Activin Receptors, Type II
Immunoglobulin Fc Fragments
Recombinant Fusion Proteins
Dalantercept has insufficient single agent activity in recurrent EMC to warrant further investigation at this dose level and schedule.